Login to Your Account



ITS' Flunisyn Elicits Strong T-Cell Response in Phase IIa

By Nuala Moran
Staff Writer

Wednesday, April 17, 2013
LONDON – Immune Targeting Systems Ltd. (ITS) presented positive data on its universal influenza vaccine, Flunisyn, showing that it induced T-cell responses in 95 percent of subjects in an elderly population, ages 65 to 74, in a Phase IIa trial.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription